Elysium Healthcare acquired by Ramsay Health Care

UNITED KINGDOM Health Providers / Healthcare Facilities / Clinics / Hospitals EV £500M–1.5bn

Context

Ramsay Health Care entered into a definitive agreement on December 13, 2021, to acquire 100% of the UK-based mental healthcare provider Elysium Healthcare from BC Partners to solidify its standing within the specialized British clinical landscape. This strategic acquisition was designed to bridge the gap between Ramsay’s existing acute medical hospitals and the specialized psychiatric and complex care segments where demand remains consistently high. By integrating these two distinct healthcare models, the group created a diversified clinical platform capable of managing patients through every stage of their recovery, from secure inpatient wards to community-based residential support. The move was strategically timed to align with broader national shifts toward integrated care models and increased public focus on mental health infrastructure and neurological rehabilitation.

Elysium Healthcare, which reported an EBITDA margin of [members only] in 2021, is valued in this transaction at an EV/EBITDA multiple of 10x–18x, standing directly in line with the average observed in the Healthcare & Pharma sector (14.8x in 2021).

-> Deep-dive in Healthcare & Pharma market trends

Target

Established as a leading independent operator within the British healthcare landscape, Elysium Healthcare specializes in the management of long-term medium and low secure hospitals alongside complex care homes designed for individuals suffering from persistent mental health conditions. The provider manages a robust network of 72 operational sites across the United Kingdom, offering approximately 2,000 beds and employing a dedicated professional workforce of more than 6,000 people.

Ent. Value

£500M–1.5bn

Equity Value

[members only]

Multiples

EV / Revenue

1x–3x

EV / EBITDA

10x–18x

EV / EBIT

[members only]

Historical Financials (GBP)

Year

Rev

EBITDA

EBIT

2021

2020

Similar deals in Health Providers

Similar deals in Health Providers
Date	Acquirer	Target	Country	Sector
02/2022	PARTNERS GROUP	FOREFRONT DERMATOLOGY	UNITED STATES	Outpatient Care
01/2022	WREN HOUSE	VOYAGE CARE	UNITED KINGDOM	Nursing Homes
12/2021	VIVALTO PARTNERS / IK PARTNERS / MACSF / ARKEA CAPITAL / BNP PARIBAS DEVELOPPEMENT	VIVALTO SANTÉ	FRANCE	Clinics / Hospitals
11/2021	CERBA HEALTHCARE	LABEXA	FRANCE	Labs (Biology)
10/2021	IVC EVIDENSIA	VETONE	FRANCE	Vet Clinics
10/2021	ARES / BPIFRANCE	POINT VISION	FRANCE	Ophthalmology
10/2021	THE CRANEMERE GROUP	OUTPATIENT IMAGING AFFILIATES	UNITED STATES	Radiology
09/2021	LIVINGBRIDGE	EVERLIGHT RADIOLOGY	UNITED KINGDOM	Radiology
08/2021	COLOSSEUM DENTAL GROUP	CURAEOS	NETHERLANDS	Dental Centers
07/2021	OMERS	AMEDES	GERMANY	Labs (Biology)

REFERENCES

Valuation range: EV £500M–1.5bn

Revenue range: £250–500M

EBITDA range: £50–100M

EV/Revenue range: 1x - 3x

EV/EBITDA range: 10x - 18x

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of Elysium Healthcare by Ramsay Health Care are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

Target: elysium healthcare

Acquirer: ramsay health care

FAQ

What transaction does this page cover?

This page covers Ramsay Health Care’s acquisition of 100% of Elysium Healthcare, a British company specialised in Healthcare Facilities, in 2021.

How was the acquisition of Elysium Healthcare by Ramsay Health Care valued, and what multiples were paid?

mynth displays the transaction’s enterprise value within the £500M–1.5bn band, its EV/EBITDA multiple within the 10x - 18x range, and its EV/revenue multiple within the 1x - 3x range. Exact figures are available to members.

What were Elysium Healthcare’s revenue and EBITDA at the time of the deal?

At the time of the transaction, Elysium Healthcare generated annual revenue estimated in the £250–500M range and EBITDA in the £50–100M bracket (FY 2021). Detailed financial figures are available to members.

How does the valuation of Elysium Healthcare compare to benchmarks in the Healthcare & Pharma sector?

With an estimated multiple range of 10x - 18x, the transaction stands directly in line with historical averages for the Healthcare & Pharma sector (14.8x in 2021).

What sources support the information on this transaction?

Data on this transaction was compiled from the official corporate announcement published by the parties, combined with independent reporting from specialized financial and M&A publications.

What is mynth?

mynth is the first free M&A database dedicated to Small & Mid-Cap transactions. We centralize Enterprise Values, revenue multiples, EBITDA multiples and transaction financials that are typically locked behind five-figure subscriptions on platforms like Capital IQ or Mergermarket. On mynth, searching and browsing deals is completely free. Our mission is simple: make professional-grade valuation intelligence accessible to every M&A advisor, independent consultant, Private Equity professional and student, without the burden of expensive annual licenses.